| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/23/2006 | WO2006031256A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 03/23/2006 | WO2006030984A1 Piperidine compound and process for preparing the same |
| 03/23/2006 | WO2006030980A1 Agent and food for preventing/improving functional digestive disorder |
| 03/23/2006 | WO2006030975A1 Piperidine derivatives and use thereof |
| 03/23/2006 | WO2006030947A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 03/23/2006 | WO2006030941A1 Simultaneous use of sulfonamide-containing compound and angiogenesis inhibitor |
| 03/23/2006 | WO2006030931A1 N-substituted n-(4-piperidinyl)amide derivative |
| 03/23/2006 | WO2006030925A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 03/23/2006 | WO2006030907A1 Retina protective agent |
| 03/23/2006 | WO2006030906A1 Nucleoside analogues or salts thereof |
| 03/23/2006 | WO2006030898A1 Aldose reductase inhibitor |
| 03/23/2006 | WO2006030851A1 Pirenoxine suspension type eye lotion |
| 03/23/2006 | WO2006030850A1 Method of preparing solution of lipid-soluble ingredient |
| 03/23/2006 | WO2006030847A1 Novel bicyclic pyrazole derivative |
| 03/23/2006 | WO2006030826A1 Medicinal composition |
| 03/23/2006 | WO2006030807A1 Carbamoylpyridone derivative having hiv integrase inhibitory activity |
| 03/23/2006 | WO2006030805A1 Triazole derivative or salt thereof |
| 03/23/2006 | WO2006030803A1 Purinenucleoside derivative modified in 8-position and medicinal use thereof |
| 03/23/2006 | WO2006030802A1 Method of screening baff suppressor or inhibitor |
| 03/23/2006 | WO2006030753A1 Therapeutic agent for keratoconjunctiva disorder |
| 03/23/2006 | WO2006030739A1 Process for production of optically active amine derivatives |
| 03/23/2006 | WO2006030450A2 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 03/23/2006 | WO2006030440A2 Use of tellurium compounds as adjuvants |
| 03/23/2006 | WO2006030438A2 Use of tellurium compounds for inhibition of interleukin-converting enzyme |
| 03/23/2006 | WO2006030402A2 Dual compartment osmotic delivery device |
| 03/23/2006 | WO2006030324A2 Testosterone stimulant |
| 03/23/2006 | WO2006030323A2 Compounds that inhibit replication of human immunodeficiency virus |
| 03/23/2006 | WO2006030306A2 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 03/23/2006 | WO2006030304A2 Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof |
| 03/23/2006 | WO2006030303A1 Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea |
| 03/23/2006 | WO2006030301A1 Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers |
| 03/23/2006 | WO2006030300A2 Processes for the preparation of olanzapine |
| 03/23/2006 | WO2006030299A1 Processes for the preparation of polymorphs of efavirenz |
| 03/23/2006 | WO2006030285A1 New 1,2,4-triazole-3-carboxamide derivatives |
| 03/23/2006 | WO2006030249A1 Donepezil salts suitable for the preparation of pharmaceutical compositions |
| 03/23/2006 | WO2006030221A1 Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent |
| 03/23/2006 | WO2006030208A1 Amino acid |
| 03/23/2006 | WO2006030124A1 Condensed pyrazole derivatives, preparation method thereof and therapeutic use of same |
| 03/23/2006 | WO2006030105A1 3-spiro-indolin-2-one derivatives as vasopressin receptor ligand |
| 03/23/2006 | WO2006030104A1 Biotinylated hexadecasaccharides, preparation and use thereof |
| 03/23/2006 | WO2006030100A1 Uses of prebiotic oligosaccharides beneficial to vaginal flora |
| 03/23/2006 | WO2006030032A1 Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | WO2006030031A1 Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | WO2006029980A1 Substituted bicyclic imidazo-3-ylamine compounds |
| 03/23/2006 | WO2006029912A1 Indole derivatives as antiviral agents |
| 03/23/2006 | WO2006029906A1 Methylene dipiperidine derivatives |
| 03/23/2006 | WO2006029863A1 Thiazolinone 2-substituted quinolines |
| 03/23/2006 | WO2006029862A1 Substituted hydantoins for the treatment of cancer |
| 03/23/2006 | WO2006029861A1 Thiazolinone 4-monosubstituted quinolines |
| 03/23/2006 | WO2006029850A1 Hydrazone derivatives and their use as beta secretase inhibitors |
| 03/23/2006 | WO2006029812A1 Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof |
| 03/23/2006 | WO2006029811A1 Method for manufacturing enantiomeric imidazole compounds |
| 03/23/2006 | WO2006029769A1 Novel 3-methyl-7-butinyl-xanthines, production thereof, and use thereof as medicaments |
| 03/23/2006 | WO2006029726A1 Dermally applicable formulations for treating skin diseases in animals |
| 03/23/2006 | WO2006029579A1 Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof |
| 03/23/2006 | WO2006029554A1 Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation |
| 03/23/2006 | WO2006029532A1 Nitrate esters and their use for mitigating cellular damage |
| 03/23/2006 | WO2006020755A9 Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
| 03/23/2006 | WO2006008133A3 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 03/23/2006 | WO2006004884A3 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| 03/23/2006 | WO2006003229A8 Pharmaceutical composition for ototopical use |
| 03/23/2006 | WO2006001954A3 Methods for promoting the formation of platelets and for treating blood and bone marrow disorders |
| 03/23/2006 | WO2005121078A3 Substituted cyclopentene compounds |
| 03/23/2006 | WO2005120486A3 Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging |
| 03/23/2006 | WO2005120474A3 Phophodiesterase 10a inhibitors to amplify the action of glp1-mimetics or dpp-iv inhibitors in diabetes |
| 03/23/2006 | WO2005120148A3 Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases |
| 03/23/2006 | WO2005118584A3 Saframycin analogs as therapeutic agents in the treatment of cancer |
| 03/23/2006 | WO2005113069A3 Use of circumin and analogues as inhibitors of acc2 |
| 03/23/2006 | WO2005108355A3 Dihydrobenzothiophenes |
| 03/23/2006 | WO2005107875A3 Triglycerides, fatty acids, alcohols as cns modulators |
| 03/23/2006 | WO2005105105A3 Kit for treating hot flashes |
| 03/23/2006 | WO2005099701A3 Methods of using sustained release aminopyridine compositions |
| 03/23/2006 | WO2005097141A3 Estrogen receptor modulators |
| 03/23/2006 | WO2005095348A3 Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| 03/23/2006 | WO2005094785A3 Compositions capable of facilitating penetration across a biological barrier |
| 03/23/2006 | WO2005092334A3 Use of n-substituted imino sugars for appetite suppression |
| 03/23/2006 | WO2005089741A3 The treatment of inflammatory disorders and pain using beta-aminoalcohols |
| 03/23/2006 | WO2005079749A3 Chitosan containing solution |
| 03/23/2006 | WO2005079284A3 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 03/23/2006 | WO2005077337A3 Dispersions prepared by use of self-stabilizing agents |
| 03/23/2006 | WO2005072779A3 Growth factor-binding compounds attached to a calixarene |
| 03/23/2006 | WO2005059133A3 Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent |
| 03/23/2006 | WO2005059111A3 DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA |
| 03/23/2006 | WO2005058366A3 Compositions comprising two different populations of polymer-active agent conjugates |
| 03/23/2006 | WO2005053639A3 Controlled release multiparticulates formed with dissolution enhancers |
| 03/23/2006 | WO2005048945A3 Hydroxylamine substituted imidazo ring compounds |
| 03/23/2006 | WO2005046658A3 Methods of modulating angiogenesis and cancer cell proliferation |
| 03/23/2006 | WO2005035549A3 Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier |
| 03/23/2006 | WO2005028434A3 Novel heterocyclic compounds as hsp90-inhibitors |
| 03/23/2006 | WO2005023819A9 Thienopyrroles as antiviral agents |
| 03/23/2006 | WO2005013886A3 Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
| 03/23/2006 | WO2005011663A8 Use of a biguanide derivative for protecting skin against uvb radiation |
| 03/23/2006 | WO2005010025A3 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 03/23/2006 | WO2005003325A3 Inhibition of viral pathogenesis |
| 03/23/2006 | WO2005000250A3 Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor |
| 03/23/2006 | WO2004105504A3 Dietary supplements and methods of preparing and administering dietary supplements |
| 03/23/2006 | WO2004096254A3 Transferrin conjugates for tumor treatment |
| 03/23/2006 | WO2004094648A3 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 03/23/2006 | WO2004087057A3 Methods for inhibition of angiogenesis |
| 03/23/2006 | WO2004064772A3 Methods and dosage forms with modified viscosity layers |